• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

byNeel MistryandTeddy Guo
June 21, 2022
in Chronic Disease, Gastroenterology
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. Clinical remission at 52 weeks was similar between ustekinumab and adalimumab.

2. Patient-reported outcomes of stool frequency and abdominal pain scores were lower in the ustekinumab group compared to adalimumab (p=0.019).

Evidence Rating Level: 1 (Excellent)

Study Rundown: First-line treatment for Crohn’s disease includes steroids, immunomodulators, and biologics. TNF inhibitors and interleukin (IL)-12 and IL-23 inhibitors represent more potent biologic options that work at the molecular level. Ustekinumab, an IL-12 and IL-23 agent, and adalimumab, anti-TNF antibody, have both shown superiority over placebo in previous trials. However, whether one biologic is more effective than the other is not well known. This randomized controlled trial aimed to compare the safety and efficacy of two relatively novel monoclonal antibodies, ustekinumab and adalimumab, in patients with moderate-to-severe active Crohn’s disease. The primary outcome was the proportion of patients in clinical remission, defined by Crohn’s Disease Activity Index (CDAI) score <150, a year after randomization. According to study results, clinical remission at 52 weeks was not significantly different between the ustekinumab and adalimumab groups. Serious and overall adverse events were also similar between groups. A major limitation of this study was that data was only reported for up to one year from baseline. Given that Crohn’s is a chronic disease, a longitudinal assessment may be warranted.

Click to read the study in The Lancet

Relevant Reading: Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

RELATED REPORTS

The rotavirus vaccine (ROTASIIL) may reduce the incidence of hospitalization for rotavirus gastroenteritis in children

Infection risk with infliximab (Remicade) and adalimumab (Humira) is similar in pediatric inflammatory bowel disease

In-depth [randomized-controlled trial]: From Jun 28, 2018, and Dec 12, 2019, 633 patients were assessed for eligibility across 121 hospitals in 18 countries. Included were patients ≥18 years of age with CDAI score between 220-450 with no response or contraindication to conventional therapy. Altogether, 386 patients (191 in ustekinumab and 195 in adalimumab) were included in the intention-to-treat analysis. The primary outcome of clinical remission was not statistically significant between treatment groups at week 52 (65% in ustekinumab vs. 61% in adalimumab, 95% confidence interval [CI] -6 to 14, p=0.42). The same was true for safety with 2% (4 of 191) patients in ustekinumab group reporting serious infections compared to 3% (5 of 195) in adalimumab group. Overall, findings from this study suggest that while both ustekinumab and adalimumab are both effective for treatment of moderate to severe active Crohn’s disease, no clinical difference in safety and efficacy was seen between the two after 52 weeks.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adalimumabbiologic naivebiologicsColitisCrohn's Diseasegastroenteritisinflammatory bowel diseaseinflammatory bowel disease (IBD)Ulcerative Colitisustekinumab
Previous Post

Unsweetened coffee consumption is associated with reduced risk of mortality

Next Post

Accelerated approval drugs incur significant fee-for-service Medicare costs

RelatedReports

Two vaccine vials on a balance scale, with graphic representations of viruses in the background, symbolizing vaccines for infectious diseases.
Emergency

The rotavirus vaccine (ROTASIIL) may reduce the incidence of hospitalization for rotavirus gastroenteritis in children

September 21, 2026
Childhood IBD collage: a boy in a hooded sweatshirt beside a hot-water bottle in a knitted cover and a thermometer
Chronic Disease

Infection risk with infliximab (Remicade) and adalimumab (Humira) is similar in pediatric inflammatory bowel disease

July 14, 2026
Psoriatic arthritis collage: an engraved joint glowing teal between two bone ends, folded knit gloves and a jar of cream
Chronic Disease

Guselkumab (Tremfya) strengthens its case for protecting joints in psoriatic arthritis

June 5, 2026
2 Minute Medicine AI Roundup editorial illustration
Oncology

Artificial intelligence predicts colorectal cancer in ulcerative colitis with 99% accuracy

September 4, 2026
Next Post

Accelerated approval drugs incur significant fee-for-service Medicare costs

Islamic-based interventions may improve both depression and anxiety

ABCD2 Score: Predicting Early Stroke Risk After Transient Ischemic Attack (TIA) [Classics Series]

SALT-ED: Normal Saline versus Balanced Crystalloids in Noncriticaly Ill Adults [Classics Series]

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Less social media usage is associated with improved internalizing symptoms in high-risk young adults.
  • AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality
  • In a phase 3 trial, tirzepatide reduced BMI versus placebo in adolescents with obesity and obesity-related complications
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.